Washington, D.C. - Instead of developing innovative, break-through therapies, pharmaceutical companies devote most of their resources to modifying existing medications, according to the latest report from the National Institute for Health Care Management Foundation (NIHCM). Release of the study further escalated already heightened rhetoric between health plans and drug makers over rising drug costs. "Highly innovative drugs are rare," said Nancy Chockley, president of NIHCM, which is supported primarily by Blue Cross and Blue Shield Assns.
A pooled review of 40 studies tied type 2 diabetes to a 53% higher Alzheimer’s risk, with incidence more than doubling when clinicians made the diagnosis.
Lockton's Sarah Klein says employers are already asking hard questions about PBM transparency, even though many of the new rules have not taken effect.
WIC participation is estimated at only 44% of eligible Medicaid enrollees in 2023, and just 15% of pregnant Medicaid enrollees. Health plans can help close that gap, but only if their referrals are tracked through enrollment.
Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.